Healthcare utilisation of 282,080 individuals with long COVID over two years: a multiple matched control, longitudinal cohort analysis

Yi Mu,Ashkan Dashtban,Mehrdad A Mizani,Chris Tomlinson,Mohamed Mohamed,Mark Ashworth,Mamas Mamas,Rouven Priedon,Steffen Petersen,Evan Kontopantelis,Kim Horstmanshof,Christina Pagel,Mevhibe Hocaoğlu,Kamlesh Khunti,Richard Williams,Johan Thygesen,Paula Lorgelly,Manuel Gomes,Melissa Heightman,Amitava Banerjee,on behalf of the CVD-COVID-UK/COVID-IMPACT Consortium
DOI: https://doi.org/10.1177/01410768241288345
2024-11-28
Journal of the Royal Society of Medicine
Abstract:Journal of the Royal Society of Medicine, Ahead of Print. ObjectivesTo investigate healthcare utilisation and cost in individuals with long COVID (LC) at population level.DesignCase–control cohort analysis with multiple age-, sex-, ethnicity-, deprivation-, region- and comorbidity-matched control groups: (1) COVID only, no LC; (2) pre-pandemic; (3) contemporary non-COVID; and (4) pre-LC (self-controlled, pre-COVID pandemic).SettingNational, population-based, linked UK electronic health records (British Heart Foundation/NHS England Secure Data Environment).ParticipantsAdults aged ≥18 years with LC between January 2020 and January 2023.Main outcome measuresHealthcare utilisation (number of consultations/visits per person: primary care (general practitioner [GP]), secondary care (outpatient [OP], inpatient [IP] and emergency department [ED], investigations and procedures) and inflation-adjusted cost (£) for LC and control populations per month, calendar year and pandemic year for each category.ResultsA total of 282,080 individuals with LC were included between January 2020 and January 2023. The control groups were COVID only, no LC (n = 1,112,370), pre-pandemic (n = 1,031,285), contemporary non-COVID (n = 1,118,360) and pre-LC (n = 282,080). Healthcare utilisation per person (per month/year) was higher in LC than controls across GP, OP and ED. For IP, LC had higher healthcare utilisation than pre-LC and contemporary non-COVID (all p < 0.0001). Healthcare utilisation of the LC group increased progressively between 2020 and 2023, compared with controls. Median cost per patient/year was also higher in individuals with LC than all control groups.ConclusionsLC has been associated with substantial, persistent healthcare utilisation and cost over the last three years. Future funding, resources and staff for LC prevention, treatment and research must be prioritised to reduce sustained primary and secondary healthcare utilisation and costs.
medicine, general & internal
What problem does this paper attempt to address?